{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T10:47:46Z","timestamp":1648896466456},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The nomenclature for antineutrophil cytoplasmic antibody (ANCA)-associated kidney disease has evolved from honorific eponyms to a descriptive-based classification scheme (Chapel Hill Consensus Conference 2012). Microscopic polyangiitis, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis do not correlate with presentation, response rates and relapse rates as when comparing myeloperoxidase versus leukocyte proteinase 3. Here we discuss the limitations of the currently used classification and propose an alternative, simple classification according to (i) ANCA type and (ii) organ involvement, which provides important clinical information of prognosis and outcomes.<\/jats:p>","DOI":"10.1093\/ckj\/sfaa255","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T22:57:51Z","timestamp":1606172271000},"page":"1327-1334","source":"Crossref","is-referenced-by-count":0,"title":["Proposal for a more practical classification of antineutrophil cytoplasmic antibody-associated vasculitis"],"prefix":"10.1093","volume":"14","author":[{"given":"Nestor","family":"Oliva-Damaso","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Hospital Costa del Sol, Marbella, Malaga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S","family":"Bomback","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"key":"2021070211233991600_sfaa255-B1","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM198806233182504","article-title":"Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis","volume":"318","author":"Falk","year":"1988","journal-title":"N Engl J Med"},{"key":"2021070211233991600_sfaa255-B2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/346520a0","article-title":"Wegener's autoantigen decoded","volume":"346","author":"Jenne","year":"1990","journal-title":"Nature"},{"key":"2021070211233991600_sfaa255-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B6","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis","volume":"33","author":"Leavitt","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10157-013-0854-0","article-title":"ACR\/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS)","volume":"17","author":"Craven","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"2021070211233991600_sfaa255-B8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1681\/ASN.2011010081","article-title":"Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis","volume":"22","author":"Falk","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.30286","article-title":"Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis","volume":"63","author":"Falk","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.2011.150714","article-title":"Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis","volume":"70","author":"Falk","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B11","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2215\/CJN.02500317","article-title":"ANCA glomerulonephritis and vasculitis","volume":"12","author":"Jennette","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B12","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: core curriculum 2020","author":"Geetha","year":"2020; 75: 124\u2013137","journal-title":"Am J Kidney Dis"},{"key":"2021070211233991600_sfaa255-B13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2021070211233991600_sfaa255-B14","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B16","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.1780330802","article-title":"The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction","volume":"33","author":"Hunder","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B18","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/art.1780330805","article-title":"The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa","volume":"33","author":"Lightfoot","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s10067-015-3086-8","article-title":"A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis","volume":"35","author":"Shah","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2021070211233991600_sfaa255-B21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2021070211233991600_sfaa255-B22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"2021070211233991600_sfaa255-B23","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/art.40471","article-title":"Brief report: circulating cytokine profiles and antineutrophil cytoplasmic antibody specificity in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"70","author":"Berti","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021070211233991600_sfaa255-B24","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","article-title":"Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"30","author":"Watts","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2021070211233991600_sfaa255-B25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3899\/jrheum.160005","article-title":"Comparison of the phenotype and outcome of quk and Japanese cohorts","volume":"44","author":"Furuta","year":"2017","journal-title":"J Rheumatol"},{"key":"2021070211233991600_sfaa255-B26","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis","volume":"8","author":"De Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B27","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/ard.60.12.1156a","article-title":"Epidemiology of vasculitis in Europe","volume":"60","author":"Watts","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ki.1995.23","article-title":"Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease","volume":"47","author":"Franssen","year":"1995","journal-title":"Kidney Int"},{"key":"2021070211233991600_sfaa255-B29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00467-016-3559-2","article-title":"Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management","volume":"33","author":"Plumb","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2021070211233991600_sfaa255-B30","first-page":"104","article-title":"Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study","volume":"30","author":"Sacri","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2021070211233991600_sfaa255-B31","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar4550","article-title":"Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study","volume":"16","author":"Sada","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2021070211233991600_sfaa255-B32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MD.0000000000000217","article-title":"Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature","volume":"93","author":"Comarmond","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2021070211233991600_sfaa255-B33","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021070211233991600_sfaa255-B34","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1046\/j.1523-1755.2000.00080.x","article-title":"Antiproteinase 3- and antimyeloperoxidase-associated vasculitis","volume":"57","author":"Franssen","year":"2000","journal-title":"Kidney Int"},{"key":"2021070211233991600_sfaa255-B35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2021070211233991600_sfaa255-B36","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B37","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/ndt\/gfu084","article-title":"ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis","volume":"29","author":"Quintana","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2021070211233991600_sfaa255-B38","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/art.22741","article-title":"Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis","volume":"56","author":"Guilpain","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B39","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2021070211233991600_sfaa255-B40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"2021070211233991600_sfaa255-B41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.V7133","article-title":"Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis","volume":"7","author":"Nachman","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B42","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000442062","article-title":"The prevalence and management of pauci-immune glomerulonephritis and vasculitis in Western countries","volume":"1","author":"Lionaki","year":"2015","journal-title":"Kidney Dis"},{"key":"2021070211233991600_sfaa255-B43","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/art.23800","article-title":"Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts","volume":"58","author":"Pagnoux","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B44","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1681\/ASN.2019060618","article-title":"Therapeutic myeloperoxidase inhibition attenuates neutrophil activation, ANCA-mediated endothelial damage, and crescentic GN","volume":"31","author":"Antonelou","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B46","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3899\/jrheum.131038","article-title":"A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis","volume":"41","author":"Mohammad","year":"2014","journal-title":"J Rheumatol"},{"key":"2021070211233991600_sfaa255-B47","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","article-title":"Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis","volume":"72","author":"Mahr","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B48","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/ndt\/gfy250","article-title":"Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort","volume":"34","author":"Berti","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2021070211233991600_sfaa255-B49","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/art.39786","article-title":"Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener's) Is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German Vasculitis Referral Center","volume":"68","author":"Schirmer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021070211233991600_sfaa255-B50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"2021070211233991600_sfaa255-B51","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.39450","article-title":"Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis","volume":"68","author":"Pu\u00e9chal","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021070211233991600_sfaa255-B53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/art.20234","article-title":"Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis","volume":"51","author":"Slot","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021070211233991600_sfaa255-B54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/BOR.0000000000000170","article-title":"Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?","volume":"27","author":"Fussner","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"2021070211233991600_sfaa255-B55","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/ard.2008.094714","article-title":"Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides","volume":"68","author":"Terrier","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B56","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2013111233","article-title":"ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease","volume":"26","author":"Kemna","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B57","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","article-title":"Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2021070211233991600_sfaa255-B58","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B59","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2215\/CJN.00100114","article-title":"Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis","volume":"9","author":"Walsh","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B60","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B61","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/rheumatology\/kex281","article-title":"Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data","volume":"56","author":"De Joode","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2021070211233991600_sfaa255-B62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B63","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1136\/annrheumdis-2015-207601","article-title":"Genetic variants in ANCA-associated vasculitis: a meta-analysis","volume":"75","author":"Rahmattulla","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021070211233991600_sfaa255-B64","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/art.39620","article-title":"HLA-DPB1 as a risk factor for relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a cohort study","volume":"68","author":"Hilhorst","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021070211233991600_sfaa255-B65","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"key":"2021070211233991600_sfaa255-B66","first-page":"671","article-title":"Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"key":"2021070211233991600_sfaa255-B67","doi-asserted-by":"crossref","first-page":"i139","DOI":"10.1093\/ndt\/gfw299","article-title":"Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis","volume":"32","author":"Sethi","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2021070211233991600_sfaa255-B68","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1681\/ASN.2006091021","article-title":"Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis","volume":"18","author":"Chen","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B69","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B70","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2215\/CJN.14561119","article-title":"Developments in the histopathological classification of ANCA-associated glomerulonephritis","volume":"15","author":"van Daalen","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B71","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7861\/clinmedicine.17-1-60","article-title":"ANCA-associated vasculitis","volume":"17","author":"Yates","year":"2017","journal-title":"Clin Med"},{"key":"2021070211233991600_sfaa255-B72","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/rheumatology\/kez148","article-title":"Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum","volume":"58","author":"Mahr","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2021070211233991600_sfaa255-B73","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/rheumatology\/keaa068","article-title":"Comment on: subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum","volume":"59","author":"Lamprecht","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2021070211233991600_sfaa255-B74","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.161224","article-title":"Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype","volume":"44","author":"Mohammad","year":"2017","journal-title":"J Rheumatol"},{"key":"2021070211233991600_sfaa255-B75","year":"2020"},{"key":"2021070211233991600_sfaa255-B76","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMe1917490","article-title":"ANCA-associated vasculitis - refining therapy with plasma exchange and glucocorticoids","volume":"382","author":"Derebail","year":"2020","journal-title":"N Engl J Med"},{"key":"2021070211233991600_sfaa255-B77","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2215\/CJN.15861219","article-title":"Treatment of granulomatosis with polyangiitis and microscopic polyangiitis: should type of ANCA guide the treatment?","volume":"15","author":"Tesar","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B78","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for anca-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2021070211233991600_sfaa255-B79","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/5\/1327\/38851775\/sfaa255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/5\/1327\/38851775\/sfaa255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T11:52:51Z","timestamp":1625226771000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/5\/1327\/6055036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,29]]},"references-count":79,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,12,29]]},"published-print":{"date-parts":[[2021,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa255","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,12,29]]}}}